ZAI LAB LTD0000006 - Asset Resilience Ratio
ZAI LAB LTD0000006 (1ZLB) has an Asset Resilience Ratio of 0.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ZAI LAB LTD0000006 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how ZAI LAB LTD0000006's Asset Resilience Ratio has changed over time. See 1ZLB total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ZAI LAB LTD0000006's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of ZAI LAB LTD0000006.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.00 Million | 0.85% |
| Total Liquid Assets | €10.00 Million | 0.85% |
Asset Resilience Insights
- Limited Liquidity: ZAI LAB LTD0000006 maintains only 0.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ZAI LAB LTD0000006 Industry Peers by Asset Resilience Ratio
Compare ZAI LAB LTD0000006's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for ZAI LAB LTD0000006 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for ZAI LAB LTD0000006.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.85% | €10.00 Million ≈ $11.69 Million |
€1.17 Billion ≈ $1.37 Billion |
-26.98pp |
| 2024-12-31 | 27.83% | €330.00 Million ≈ $385.80 Million |
€1.19 Billion ≈ $1.39 Billion |
+26.26pp |
| 2023-12-31 | 1.57% | €16.30 Million ≈ $19.06 Million |
€1.04 Billion ≈ $1.21 Billion |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€1.22 Billion ≈ $1.43 Billion |
-- |
| 2021-12-31 | 27.64% | €445.00 Million ≈ $520.25 Million |
€1.61 Billion ≈ $1.88 Billion |
-- |
About ZAI LAB LTD0000006
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more